Incyte will acquire Vega Therapeutics, a subsidiary of Star Therapeutics, to advance the development of VGA039, an investigational monthly injection therapy to prevent bleeds…
Von Willebrand disease
Von Willebrand disease is a genetic bleeding disorder that impairs the body’s ability to form proper blood clots. It can cause frequent or prolonged bleeding episodes, but many people experience only mild or manageable symptoms.
Treatment for von Willebrand disease focuses on preventing and controlling bleeding to improve daily life and reduce serious risks. Management plans vary by disease type and may involve ongoing monitoring and personalized care strategies.
Latest news
Discussion
People with von Willebrand disease (VWD) had lower bone mineral density than healthy individuals in a small, single-center study, highlighting the need to consider…